Beforepay FY26 slides: profit surges 57% on loan growth

Beforepay delivered a strong FY26 with cash NPAT of $15.7M, up 57% (and cited as a fourfold increase over two years), alongside revenue up 26% to $50.6M. Growth was driven by total advances of $963M (+19% YoY), including a sharp 728% surge in Personal Loans and a Pay Advance repricing shift that management says didn’t change default/reuse behavior meaningfully. The new $100M debt facility (with $35.9M drawn and $19.1M undrawn) is expected to generate $1M+ annual savings and support scaling toward roughly doubling originations, though net bad debts rose to 0.5% overall (Personal Loans 3.3%) as provisioning sensitivity to rapid growth increases.

Analysis

The cleanest takeaway is not the headline earnings beat, but the operating model inflection: a small lender that can scale loan volume faster than headcount is starting to convert incremental revenue into disproportionate equity returns. That is the setup where the market usually pays up on forward numbers, but only if credit loss timing stays benign; in this business, reported profitability can look stable right up until arrears migrate and provisioning snaps higher.

The second-order issue is balance-sheet intensity. The move into longer-duration loans materially increases funding sensitivity versus the legacy short-duration product, so the new facility is a real enabler but also a larger transmission channel if wholesale spreads widen or deposit/funding competition in consumer credit tightens. Over the next 1-3 months, the stock likely trades on whether management can show that the new pricing/model regime keeps losses contained while originations continue to accelerate; over 6-18 months, the risk is that growth itself forces the market to value the book more like a cyclical lender than a fintech compounder.

Contrarian view: the market may still be underestimating the optionality in automation and B2B credit analytics, which could support a higher multiple if Carrington Labs starts to matter. But the consensus seems to be missing that this is now partly a duration trade on consumer credit conditions: a mild macro soft patch, rising unemployment, or funding-cost repricing would hit this name faster than the average listed fintech because the equity base is still thin relative to the expanding loan book.

Key Decisions for Investors

• Buy B4P on post-result weakness, but size as a credit-cycle trade rather than a pure growth compounder; 3-6 month upside comes from FY27 earnings revisions if arrears stay contained, while downside is a rapid de-rating if provisioning rises.
• Use a tight risk line: reduce/exit if overall bad debts move materially above current levels or if management signals funding-cost pressure; the thesis weakens quickly if the market starts pricing in a higher loss curve.
• If liquidity allows, pair long B4P against a basket of more manual, slower-moving consumer lenders/fintechs to isolate the underwriting automation advantage; this is a relative-value trade on execution quality over 6-12 months.
• For conservative accounts, prefer a call-spread style expression over outright equity if available: the upside is an FY27 estimate reset, but the stock remains vulnerable to one bad provisioning print.